Ubelgiji - Kiingereza - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

b. braun melsungen ag - ropivacaine hydrochloride monohydrate 10,58 mg/ml - eq. ropivacaine hydrochloride 10 mg/ml - solution for injection - 10 mg/ml - ropivacaine hydrochloride monohydrate 10.58 mg/ml - ropivacaine

Marekani - Kiingereza - NLM (National Library of Medicine)

b. braun medical inc. - sodium chloride (unii: 451w47iq8x) (sodium cation - unii:lyr4m0nh37), potassium chloride (unii: 660yq98i10) (potassium cation - unii:295o53k152), calcium chloride (unii: m4i0d6vv5m) (calcium cation - unii:2m83c4r6zb), magnesium chloride (unii: 02f3473h9o) (magnesium cation - unii:t6v3lhy838), sodium acetate (unii: 4550k0sc9b) (sodium cation - unii:lyr4m0nh37), sodium citrate (unii: 1q73q2julr) (sodium cation - unii:lyr4m0nh37) - for use as an extraocular and intraocular irrigating solution during ocular surgical procedure involving perfusion of the eye with an expected maximum duration of less than 60 minutes.

Marekani - Kiingereza - NLM (National Library of Medicine)

avera mckennan hospital - dexmethylphenidate hydrochloride (unii: 1678ok0e08) (dexmethylphenidate - unii:m32rh9mfgp) - dexmethylphenidate hydrochloride 20 mg - dexmethylphenidate hydrochloride extended-release capsules are indicated for the treatment of attention deficit hyperactivity disorder (adhd) in patients aged 6 years and older. the effectiveness of dexmethylphenidate hydrochloride extended-release capsules in the treatment of adhd in patients aged 6 years and older was established in 2 placebo-controlled studies in patients meeting dsm-iv criteria for adhd [see clinical studies (14) ]. a diagnosis of attention deficit hyperactivity disorder (adhd; dsm-iv) implies the presence of hyperactive-impulsive or inattentive symptoms that caused impairment and were present before age 7 years. the symptoms must cause clinically significant impairment, e.g., in social, academic, or occupational functioning, and be present in 2 or more settings, e.g., school (or work) and at home. the symptoms must not be better accounted for by another mental disorder. for the inattentive type, at least 6 of the following symptoms must have persisted for at least 6 months: lack of atten

Marekani - Kiingereza - NLM (National Library of Medicine)

sandoz inc - dexmethylphenidate hydrochloride (unii: 1678ok0e08) (dexmethylphenidate - unii:m32rh9mfgp) - dexmethylphenidate hydrochloride 5 mg - dexmethylphenidate hydrochloride extended-release capsules are indicated for the treatment of attention deficit hyperactivity disorder (adhd) [see clinical studies (14)]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to adhd medications, including dexmethylphenidate hydrochloride extended-release capsules, during pregnancy. healthcare providers are encouraged to register patients by calling the national pregnancy registry for adhd medications at 1-866-961-2388 or visit https://womensmentalhealth.org/adhd-medications/. risk summary dexmethylphenidate is the d-threo enantiomer of racemic methylphenidate. published studies and postmarketing reports on methylphenidate use during pregnancy have not identified a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. there may be risks to the fetus associated with the use of cns stimulants use during pregnancy (see clinical considerations ). embryo-fetal

Marekani - Kiingereza - NLM (National Library of Medicine)

par pharmaceuticals, inc. - dexmethylphenidate hydrochloride (unii: 1678ok0e08) (dexmethylphenidate - unii:m32rh9mfgp) - dexmethylphenidate hydrochloride 15 mg - dexmethylphenidate hydrochloride extended-release capsules is indicated for the treatment of attention deficit hyperactivity disorder (adhd) [see clinical studies (14)] . - hypersensitivity to methylphenidate or other components of dexmethylphenidate hydrochloride extended-release capsules. hypersensitivity reactions such as angioedema and anaphylactic reactions have been reported in patients treated with methylphenidate [see adverse reactions (6.1)] . - concomitant treatment with monoamine oxidase inhibitors (maois) or within 14 days following discontinuation of treatment with an maoi, because of the risk of hypertensive crises [see drug interactions (7.1)] . pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to adhd medications, including dexmethylphenidate hydrochloride extended-release capsules, during pregnancy. healthcare providers are encouraged to register patients by calling the national pregnancy registry for adhd medications at 1-

Marekani - Kiingereza - NLM (National Library of Medicine)

virtus pharmaceuticals - chlordiazepoxide hydrochloride (unii: mfm6k1xwdk) (chlordiazepoxide - unii:6rz6xez3cr), clidinium bromide (unii: 91zqw5jf1z) (clidinium - unii:bo76jf850n) - chlordiazepoxide hydrochloride 5 mg - chlordiazepoxide hydrochloride/clidinium bromide is indicated to control the emotional and somatic factors in gastrointestinal disorders. chlordiazepoxide hydrochloride/clidinium bromide may also be used as adjunctive therapy in the treatment of peptic ulcer and in the treatment of irritable bowel syndrome (irritable colon, spastic colon, mucous colitis) and acute enterocolitis. chlordiazepoxide hydrochloride/clidinium bromide is contraindicated in the presence of glaucoma (since the anticholinergic component may produce some degree of mydriasis) and in patients with prostatic hypertrophy and benign bladder neck obstruction. it is contraindicated in patients with known hypersensitivity to chlordiazepoxide hydrochloride and/or clidinium bromide. withdrawal symptoms, similar in character to those noted with barbiturates and alcohol (convulsions, tremor, abdominal and muscle cramps, vomiting and sweating), have occurred following abrupt discontinuance of chlordiazepoxide. the more severe withdrawal symptoms have

Malta - Kiingereza - Medicines Authority

b braun melsungen ag carl-braun-strasse 1, d34212 melsungen, germany - sodium chloride - solution for injection - sodium chloride 0.9 % (w/v) - all other non-therapeutic products

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

b. braun medical limited - leucine isoleucine lysine hydrochloride dl-methionine phenylalanine threonine tryptophan, l- valine arginine histidine aminoacetic acid alanine proline aspartic acid aspargine monohydrate acetylcysteine glutamic acid ornithine hydrochloride serine tyrosine sodium acetate trihydrate potassium acetate magnesium acetate tetrahydrate sodium phosphate monobasic malic acid n-acetyltyrosine ph. eur. - solution for infusion - 10 %w/v

Ayalandi - Kiingereza - HPRA (Health Products Regulatory Authority)

b. braun melsungen ag - poly(o-2-hydroxyethyl)starch sodium chloride - solution for infusion - 10% %w/v

Australia - Kiingereza - Department of Health (Therapeutic Goods Administration)

b braun australia pty ltd - sodium chloride -